💨 Abstract
Amicus Therapeutics Inc. reported a $21.7 million loss in Q1 2025, falling short of Wall Street's earnings expectation of 8 cents per share. The company also posted revenue of $125.2 million, missing the forecasted $135.6 million. The results were generated by Automated Insights using data from Zacks Investment Research.
Courtesy: wtop.com
Summarized by Einstein Beta 🤖
Suggested
Scientists once thought only humans could bob to music. Ronan the sea lion helped prove them wrong -
Cadena de sándwiches Subway sigue reduciendo su operación en EE.UU. -
Sheinbaum informa que tuvo una conversación “muy positiva” con Trump -
Qué implica la presentación del primer cargo por terrorismo en EE.UU. contra un presunto miembro del Tren de Aragua -
Prosecutors in Thailand say they won’t pursue royal defamation case against US scholar -
National security adviser Mike Waltz and his deputy are leaving Trump White House -
Encuentran su cuerpo cubierto de concreto en Prince George’s; acusan a su novio de homicidio
Barcelona defender Koundé faces a spell out with hamstring injury -
Llegan los últimos barcos de China sin aranceles. La cuenta regresiva para la escasez y el aumento de precios ha comenzado -
Canada hires World Cup-winning coach Gordie Herbert to take over men’s national basketball team -
Powered by MessengerX.io